Clinical trials: Lung Cancer Non-small Cell Stage IV
Non-Squamous Non-Small Cell Lung Cancer
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
This 4 arm study in patients with advanced Stage IIIb/IV non-small cell cancer (NSCLC) who failed at least one standard chemotherapy regimen will determine the proportion of patients with progression-free survival at 12 weeks…
- Trial name
- NCT00760929
- Testing
- RG1507, erlotinib [Tarceva]
- Where
- 57 sites in United States, Australia and 9 more
- Volunteers
- 171 people
- Sponsor
- Hoffmann-La Roche
Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy
The purpose of this study is to determine the maximum dose that is safely tolerated of the experimental drug Rhenium Re 188 P2045.
- Conditions
- Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell, Neoplasm Recurrence, Local
- Trial name
- NCT00100256
- Testing
- Rhenium (Re 188 P2045, BAY86-5284)
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Andarix Pharmaceuticals
Non-small Cell Lung Cancer Metastatic
Predictive Multimodal Signatures Associated With Response to Treatment and Prognosis of Patients With Stage IV Non-small Cell Lung Cancer
Predicting response to therapy and disease progression in stage IV NSCLC patients treated with pembrolizumab monotherapy, chemotherapy-pembrolizumab combination therapy or chemotherapy alone in the first-line setting.
- Trial name
- DEEP-Lung-IV (NCT04994795)
- Testing
- Predictive models (data collection)
- Where
- 30 sites in United States, Brazil and 6 more
- Volunteers
- 4,000 people
- Sponsor
- Sophia Genetics SAS
Lung Cancer, Non-Small Cell Lung Cancer
A Phase 2 Study Evaluating ABT-751 in Combination With Taxotere in Advanced Non-Small Cell Lung Cancer
To determine the efficacy of ABT-751 when administered in combination with standard docetaxel in subjects with advanced or metastatic NSCLC.
- Trial name
- NCT00354562
- Testing
- ABT-751, Docetaxel
- Where
- 32 sites in United States, Canada and 2 more
- Volunteers
- 75 people
- Sponsor
- Abbott
Solid Tumors, Advanced Malignancies
Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)
This is an open-label, Phase 1/2 study in subjects with advanced or metastatic solid tumors. The study has three separate treatment groups where separate epigenetic agents are evaluated with an immunotherapy combination.
- Conditions
- Solid Tumors, Advanced Malignancies, Metastatic Cancer
- Trial name
- NCT02959437
- Testing
- Azacitidine, Pembrolizumab, Epacadostat
- Where
- 12 sites in United States, Spain and 1 more
- Volunteers
- 70 people
- Sponsor
- Incyte Corporation
Non-small Cell Lung Cancer
A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(PANKU-Lung04)
This trial is a registered phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in combination with osimertinib versus osimertinib as first-Line treatment in patients with…
- Trial name
- NCT06838273
- Testing
- BL-B01D1, Osimertinib
- Where
- China
- Volunteers
- 720 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Non-Small Cell Lung Cancer
A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Non-Small Cell Lung Cancer
The purpose of this study is to determine whether BIIB022, Paclitaxel and Carboplatin are effective in the treatment of Treatment-Naive, Stage IIIB/IV Non-Small Cell Lung Cancer.
- Trial name
- NCT00970580
- Testing
- BIIB022 With Paclitaxel and Carboplatin
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Biogen
Non-small Cell Lung Cancer (NSCLC)
Study of Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Platinum-based Doublet Chemotherapy as First-line Treatment for Participants With Locally Advanced or Metastatic NSCLC.
The primary scientific question of interest is whether the addition of ociperlimab to platinum-based chemotherapy and tislelizumab improve progression-free survival (PFS) or overall survival (OS) compared to pembrolizumab and…
- Trial name
- AdvanTIG-306 (NCT05791097)
- Testing
- Ociperlimab, Tislelizumab, Pembrolizumab
- Sponsor
- Novartis Pharmaceuticals
Carcinoma, Non-Small-Cell Lung, Metastatic Non Small Cell Lung Cancer
CISH Inactivated TILs in the Treatment of NSCLC
A clinical trial to assess the safety and efficacy of genetically-engineered Tumor Infiltrating Lymphocytes (TIL) in which the intracellular immune checkpoint CISH has been inhibited using CRISPR gene editing for the treatment of…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Metastatic Non Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Squamous Cell Lung Cancer
- Trial name
- CheckCell-2 (NCT05566223)
- Testing
- Fludarabine, Cyclophosphamide, CISH Inactivated TIL
- Where
- 2 sites in United States
- Sponsor
- Intima Bioscience, Inc.
Hepatocellular Cancer, Squamous-Cell Non-Small Cell Lung Cancer
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)
HCC is a common cancer worldwide and a leading cause of cancer-related death. Lung cancer is the most frequently diagnosed cancer in the world, and the leading cause of cancer deaths.
- Trial name
- NCT06858813
- Testing
- Lenvatinib, ABBV-324
- Where
- 22 sites in United States, China and 5 more
- Volunteers
- 232 people
- Sponsor
- AbbVie
NSCLC (Advanced Non-small Cell Lung Cancer)
A Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for First-line Treatment in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This is a Randomized, Double-Blind, Multicenter, Phase II/III Study to Evaluate HLX37 (Recombinant Human Anti-PD-L1 and Anti-VEGF Bispecific Antibody) in Combination with Chemotherapy Versus Pembrolizumab in Combination with…
- Trial name
- NCT07865910
- Testing
- Investigational drug: HLX37 dose1, IV, Q3W, PEMBROLIZUMAB (alone or when added to a regimen above), Carboplatin (Investigator discretion)
- Where
- 16 sites in China
- Volunteers
- 1,438 people
- Sponsor
- Shanghai Henlius Biotech
Non-small Cell Lung Cancer
SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer.
This multi-center, open label Phase II/III clinical study is performed in patients with locally advanced/metastatic NSCLC progressed on prior EGFR-TKI treatment or with non TKI-sensitizing mutation or patients with EGFR exon20ins…
- Trial name
- NCT05020769
- Testing
- SI-B001, Osimertinib
- Where
- 3 sites in China
- Volunteers
- 14 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Lung Cancer, Non-Small Cell Lung Cancer
Pegfilgrastim Given Same Day As or Day After Carboplatin and Docetaxel in Advanced Metastatic Non-Small Cell Lung Cancer (NSCLC)
The purpose of this research study is to evaluate the safety and effectiveness of Neulasta® (pegfilgrastim) in reducing infection when given on the same day versus one day after the completion of chemotherapy (docetaxel and…
- Trial name
- NCT00094822
- Testing
- PI Discretion
- Volunteers
- 90 people
- Sponsor
- Amgen
Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic
A Study of LY01008 and Bevacizumab Combined With Paclitaxel and Carboplatin for Treatment of Naïve Subjects With Metastatic or Recurrent Nonsquamous Non-small Cell Lung Cancer
This is a Randomized, Double-blind, Multicenter Phase III Study Comparing Efficacy and Safety of LY01008 (Recombinant Humanized Anti-Human Vascular Endothelial Growth Factor Monoclonal Antibody Injection) and Bevacizumab Combined…
- Conditions
- Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer Recurrent
- Trial name
- NCT03533127
- Testing
- LY01008, Bevacizumab
- Where
- China
- Volunteers
- 648 people
- Sponsor
- Luye Pharma Group Ltd.
Non-Small Cell Lung Cancer
A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib
This is a multicenter, open-label phase 2 study that will enroll KRASG12C mutated patients with locally advanced or metastatic NSCLC, receiving treatment (ABSK043 in combination with Glecirasib) in a 21-day combination cycle.
- Trial name
- NCT07164170
- Testing
- ABSK043 in combination with Glecirasib
- Where
- 17 sites in China
- Volunteers
- 86 people
- Sponsor
- Abbisko Therapeutics Co, Ltd
Recurrent Non-Small Cell Lung Cancer
Dose Escalation Trial of Intra-Tumoral Injection of NIS Measles Virus in Combination With Atezolizumab
This a Phase 1 study designed to determine the maximum tolerated dose (MTD) and toxicity of attenuated Measles virus (MV-NIS) combined with Atezolizumab in patients with recurrent and metastatic NSCLC.
- Trial name
- NCT02919449
- Testing
- MV-NIS, Atezolizumab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Vyriad, Inc.
Non-Small Cell Lung Cancer
Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer
The purpose of this study is to compare the combination of pemetrexed and carboplatin with the combination of docetaxel and carboplatin in terms of survival without Grade 3 or 4 toxicity in previously untreated patients with…
- Trial name
- NCT00520676
- Testing
- pemetrexed, docetaxel, carboplatin
- Where
- 20 sites in Australia, Brazil and 4 more
- Volunteers
- 260 people
- Sponsor
- Eli Lilly and Company
Non-Small-Cell Lung Adenocarcinoma, Non-small Cell Lung Cancer Stage IIIB
A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC
The purpose of this study is to determine whether combining ganetespib (STA-9090) with docetaxel is more effective than docetaxel alone in the treatment of patients with advanced non-small cell lung cancer.
- Conditions
- Non-Small-Cell Lung Adenocarcinoma, Non-small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Metastatic
- Trial name
- Galaxy 2 (NCT01798485)
- Testing
- Docetaxel, Ganetespib
- Where
- 267 sites in United States, Austria and 18 more
- Volunteers
- 696 people
- Sponsor
- Synta Pharmaceuticals Corp.
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma
The purpose of this study is to predict responses to Erbitux as a single agent in patients with Non Small Cell Lung Cancer
- Trial name
- NCT00207116
- Testing
- Cetuximab
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Eli Lilly and Company
Prostate Cancer, Non Small Cell Lung Cancer
First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine
OVM-200 will be tested in humans for the first time in Study OVM-200-100. Up to 52 patients aged 18-75 with prostate, lung or ovarian cancer will be enrolled in the Study to find out if OVM-200 is safe to continue studying it in…
- Conditions
- Prostate Cancer, Non Small Cell Lung Cancer, Ovarian Cancer
- Trial name
- NCT05104515
- Testing
- OVM-200
- Where
- 4 sites in United Kingdom
- Volunteers
- 36 people
- Sponsor
- Oxford Vacmedix UK Ltd.